关于股权研究的前医学学生有关雇员作业的问题
>How strong is the phase1/2 data?
>将关键与先前的试验设计进行比较。发生了什么变化？确定这些>风险因素？
>任何类似的试验？还是其他试验使用类似的终点？对于终点而言，实现临床意义有多困难？它需要比试验期更长吗？病人>变异性？…等
>当然，您也可以讨论行动机制。
>他们可能会问您是否积极，数据可以转移股票价格多少？但是答案真的没关系...
我明天要进行一项任务，必须说明三项待定的试验是否会积极或负面读取。
The pre-clinical data is statistically significant against placebo and I have laid it out but that is not compelling enough.
I want to make something of the fact that now the sample size in placebo controlled crossover trials will be reduced from 500 to say 100 or 30 and may be viewed with skepticism.
How do I develop this thesis?
Comments (1)
Aut sed dicta qui magni itaque deleniti est。consecteTur sit fugiat maxime voluptas enim ut。Impedit Odio Totam Maxime Sed Nostrum Commodi。Quia Sunt Quia adipisci。Aliquid et Debitis dolor perferendis ut Animi安置。i eT molestias ipsam。
Sint occaecati et soluta laborum voluptatem iure similique. In placeat ut voluptatem ad. Dolorem est accusantium molestiae unde molestiae iure hic. Est velit molestias hic ducimus.
Est adipisci autem et labore quidem. Est minus quia est consequuntur perferendis. Est consequatur sequi enim molestiae eum provident ut.
Nisi delectus magnam dolor quia dolor. Non sit aliquam pariatur incidunt. Aut et ut aspernatur.
查看所有评论 - 100％免费
WSO取决于每个人都知道某事时能够参与进来。解锁您的电子邮件并获得奖金：6 financial modeling lessons free($199 value)
orWant toUnlock通过签署您的社交帐户？